BCL2 and breast carcinoma: In ovarian and breast cancers, it has been reported that overexpression of ITGAV and ITGB3 promotes cancer pro-survival pathways by increased expression of BCL-2 (B-cell leukemia/lymphoma 2) antiapoptotic family proteins and triggering PI3-K/Akt and Ras-Raf-ERK/MAPK pathways for cancer cell proliferation and survival from chemotherapy and/or ionizing radiation [27].